American Board of Medical Specialties competitors

Robert W. Carlson is a Professor:Medicine at Stanford University Medical Center Auxiliary, Member at American Society of Clinical Oncology (ASCO), and Medical Dir:Inpatient Oncology at STANFORD CANCER INSTITUTE and is based in Plymouth Meeting, Pennsylvania. He has experience at Stanford University, Stanford Hospital & Clinics, and American Society of Clinical Oncology (ASCO). Robert attended Stanford University between 1970 and 1974 and Stanford University School of Medicine between 1974 and 1978.

Mike S. Perry was appointed as Chief Executive Officer (CEO) of AVITA Medical in June 2017, after serving on the Board since February 2013. He brings extensive experience across the global pharmaceutical value chain for healthcare products spanning diverse therapeutic areas, including substantial expertise in cell therapies and cell-based gene therapies. In his career, he has been materially involved in the successful development and commercial launch of over 30 prescription products, 14 of which achieved blockbuster status. Prior to joining AVITA, Dr. Perry’s leadership positions included Chief Scientific Officer of Novartis’ Cell and Gene Therapy Unit from 2014-2017; Vice President and Global Head of Stem Cell Therapy for Novartis Pharmaceuticals Corp. from 2012-2014. With additional positions held as Global Head of R&D at Baxter Healthcare; President and CEO of Cell & Gene Therapy at Novartis affiliates Systemix Inc. and Genetic Therapy, Inc.; Vice President of Regulatory Affairs at Sandoz Pharmaceuticals Corporation; Director of Regulatory Affairs at Schering-Plough Corporation; and Venture Partner with Bay City Capital, LLC, Dr. Perry brings successful global management, guidance and forward direction to AVITA. Since 2011, has served as a Director with Arrowhead Pharmaceutical expanding his reach in influential medical growth.